Trial · NCT03765918
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pembrolizumab + Standard of Care (SOC) | 363 | |
| Overall Study | STARTED | Standard of Care (SOC) | 351 | |
| Overall Study | Treated | Pembrolizumab + Standard of Care (SOC) | 360 | |
| Overall Study | Treated | Standard of Care (SOC) | 316 | |
| Overall Study | Safety Analysis Population | Pembrolizumab + Standard of Care (SOC) | 361 | |
| Overall Study | Safety Analysis Population | Standard of Care (SOC) | 315 | |
| Overall Study | Efficacy Analysis Population | Pembrolizumab + Standard of Care (SOC) | 363 | |
| Overall Study | Efficacy Analysis Population | Standard of Care (SOC) | 351 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 GHS/QoL (Items 29 & 30) Assessment | Pembrolizumab + Standard of Care (SOC) | 354 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 GHS/QoL (Items 29 & 30) Assessment | Standard of Care (SOC) | 0 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 GHS/QoL (Items 29 and 30) Assessment | Pembrolizumab + Standard of Care (SOC) | 356 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 GHS/QoL (Items 29 and 30) Assessment | Standard of Care (SOC) | 306 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 (Items 1-5) Assessment | Pembrolizumab + Standard of Care (SOC) | 354 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 (Items 1-5) Assessment | Standard of Care (SOC) | 0 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 (Items 1-5) Assessment | Pembrolizumab + Standard of Care (SOC) | 356 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-C30 (Items 1-5) Assessment | Standard of Care (SOC) | 306 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-H&N35 (Items 35-38) Assessment | Pembrolizumab + Standard of Care (SOC) | 354 | |
| Overall Study | Neoadjuvant Treatment Period: Participants Who Took EORTCQLQ-H&N35 (Items 35-38) Assessment | Standard of Care (SOC) | 0 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-H&N35 (Items 35-38) Assessment | Pembrolizumab + Standard of Care (SOC) | 356 | |
| Overall Study | Adjuvant Treatment Period: Participants Who Took EORTCQLQ-H&N35 (Items 35-38) Assessment | Standard of Care (SOC) | 306 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03765918/flow